Depo Provera Lawsuit News & Updates
Florida federal court hosts MDL 3091 for women alleging meningioma after long-term Depo-Provera injections. Use this page for hearing calendars, warning-label shifts, and plain-language context before requesting a free, confidential review.
Last updated: May 13, 2026
Depo-Provera Litigation at a Glance
No. 3091 (N.D. Fla.)
Hon. M. Casey Rodgers
1,750+ pending
Late May 2026 – Rule 702 hearings
Latest Depo Provera Lawsuit Update
Judge Rodgers’ MDL 3091 docket bundles discovery on warnings, epidemiology, and company documents while leaving each meningioma plaintiff with a separate case number. Expect heavy expert gatekeeping in 2026; outcomes will still vary plaintiff by plaintiff.
Current Depo Provera Lawsuit News
- •More than 1,750 lawsuits pending in the Depo-Provera MDL before Judge M. Casey Rodgers
- •FDA approved a new meningioma warning for the Depo-Provera label (December 2025)
- •Rule 702 / Daubert expert causation hearings scheduled for late May 2026
- •Parallel state court filings continue in Delaware, New York, California, and other states
- •No global settlement yet; litigation remains in pretrial phase
Legal Case Updates: MDL and Depo Provera Litigation
Depo Provera litigation is centralized in In re: Depo-Provera (Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3091, in the Northern District of Florida. This consolidation streamlines discovery, bellwether selection, and rulings on common legal and scientific issues. Plaintiffs allege that long-term use of Depo-Provera increased their risk of meningioma and that the manufacturer failed to adequately warn about Depo Provera side effects and Depo Provera health risks.
Why This Isn't a Depo Provera Class Action
An MDL is different from a class action. In a Depo Provera class action, one outcome would apply to the whole group. In the MDL, each plaintiff keeps an individual case and any settlement or verdict is based on that person's injuries and damages. This structure typically allows for higher compensation for those with more severe harm.
Key Dates and Legal Developments
| Date / Period | Development |
|---|---|
| 2024 | Landmark BMJ study and other research strengthen link between long-term Depo-Provera use and meningioma; litigation filings increase. |
| 2025 | MDL formed; cases centralized in Northern District of Florida. Additional studies (UBC, Cleveland Clinic) support causation. FDA approves updated Depo-Provera label with meningioma warning (Dec 2025). |
| Late May 2026 | Rule 702 / expert causation hearings scheduled; outcomes may affect which cases can proceed to trial. |
| Ongoing | New Depo Provera injury lawsuits continue to be filed; state court cases proceed in parallel where applicable. |
Science & Evidence Behind the Claims
Peer-reviewed research has established a link between long-term Depo-Provera use and intracranial meningioma. Courts and plaintiffs rely on this body of evidence when evaluating failure-to-warn and causation. Key studies include:
BMJ French Study (2024)
University of British Columbia (2025)
Cleveland Clinic / JAMA Neurology (2025)
For a deeper dive, read Depo-Provera and Brain Tumors: What the Latest Research Shows and Understanding the Scientific Evidence Linking Depo Provera to Brain Tumors.
Think You May Qualify?
If you used Depo-Provera and were diagnosed with a meningioma, you may be eligible for a free case review. Get the full picture on eligibility, settlement tiers, and how to get connected with a law firm.
Depo-Provera Lawsuit – Free Case ReviewFrequently Asked Questions
Ready to See If You Qualify?
Free, confidential case review. No obligation. We may connect you with an independent law firm if appropriate.
Start Free Case ReviewDisclaimer
This Depo Provera lawsuit news page is for informational purposes only and does not constitute legal advice. Top Tier Legal LLC is not a law firm. Litigation status and dates may change. For the most current Depo Provera lawsuit update and to see if you qualify for a free case review, visit our Depo-Provera lawsuit page or contact us.